New directions in the treatment of opioid withdrawal.
Srivastava AB, Mariani JJ, Levin FR.
Lancet. 2020 Jun 20;395(10241):1938-1948. doi: 10.1016/S0140-6736(20)30852-7.
Neonatal Abstinence Syndrome.
Jansson LM, Patrick SW.
Pediatr Clin North Am. 2019 Apr;66(2):353-367. doi: 10.1016/j.pcl.2018.12.006.
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
D'Onofrio G, Herring AA, Perrone J, Hawk K, Samuels EA, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall MR, Walsh SL, Dziura J, Fiellin DA.
JAMA Netw Open. 2024 Jul 1;7(7):e2420702. doi: 10.1001/jamanetworkopen.2024.20702.
Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations.
Coe MA, Lofwall MR, Walsh SL.
J Addict Med. 2019 Mar/Apr;13(2):93-103. doi: 10.1097/ADM.0000000000000457.
Historical Review: Opiate Addiction and Opioid Receptors.
Wang S.
Cell Transplant. 2019 Mar;28(3):233-238. doi: 10.1177/0963689718811060. Epub 2018 Nov 13.
Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach.
Cohen SM, Weimer MB, Levander XA, Peckham AM, Tetrault JM, Morford KL.
J Addict Med. 2022 Jul-Aug 01;16(4):399-406. doi: 10.1097/ADM.0000000000000945. Epub 2021 Dec 23.
Clinical pharmacology of opioids for pain.
Inturrisi CE.
Clin J Pain. 2002 Jul-Aug;18(4 Suppl):S3-13. doi: 10.1097/00002508-200207001-00002.
The fragile state of opioid withdrawal.
Wong W.
Sci Signal. 2023 Feb 14;16(772):eadh0620. doi: 10.1126/scisignal.adh0620. Epub 2023 Feb 14.
Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS).
Mangat AK, Schmölzer GM, Kraft WK.
Semin Fetal Neonatal Med. 2019 Apr;24(2):133-141. doi: 10.1016/j.siny.2019.01.009. Epub 2019 Feb 5.
Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review.
Spreen LA, Dittmar EN, Quirk KC, Smith MA.
Pharmacotherapy. 2022 May;42(5):411-427. doi: 10.1002/phar.2676. Epub 2022 Mar 25.
